SecProbe.io

United States securities and exchange commission logo
May 7, 2020
Steven M. Fruchtman, M.D.
Chief Executive Officer
Onconova Therapeutics, Inc.
375 Pheasant Run
Newtown, PA 18940
Re:Onconova Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 24, 2020
File No. 333-237844
Dear Dr. Fruchtman:
            We have limited our review of your registration statement to those issues we have
addressed in our comment. Please respond to this letter by amending your registration statement
and providing the requested information.  If you do not believe our comment applies to your
facts and circumstances or do not believe an amendment is appropriate, please tell us why in
your response.
            After reviewing any amendment to your registration statement and the information you
provide in response to this comment, we may have additional comments.
Registration Statement on Form S-3 filed on April 24, 2020
General
1.We note Onconova's representation in correspondence to the staff dated November 12,
2019 at page 3 that the company would "add the following risk factor disclosure
describing the Company’s forum selection provision and its intent in the Company’s
future Annual Reports on Form 10-K and in future registration statements," but are unable
to determine where you have done so in either your Form 10-K for the fiscal year ended
December 31, 2019, or in the instant registration statement on Form S-3. Please advise or
revise.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Refer to Rules 460 and 461 regarding requests for acceleration.  Please allow adequate

 FirstName LastNameSteven M. Fruchtman, M.D.
 Comapany NameOnconova Therapeutics, Inc.
 May 7, 2020 Page 2
 FirstName LastName
Steven M. Fruchtman, M.D.
Onconova Therapeutics, Inc.
May 7, 2020
Page 2
time for us to review any amendment prior to the requested effective date of the registration
statement.
            Please contact Paul Fischer, Staff Attorney, at 202-551-3415 or Celeste M. Murphy,
Legal Branch Chief, at 202-551-3257 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Joanne Soslow, Esq.